1. person diagnosed with covid-19 infection. 2. pregnant at the time of screening or breastfeeding. 3. known allergy or hypersensitivity to hcq or other aminoquinoline compounds. 4. already on hcq for different indications (e.g., rheumatological diseases, malaria prophylaxis) 5. diagnosis of other systemic viral or bacterial infection. 6. use of systemic immunosuppressant agents within 90 days of enrollment (e.g., corticosteroids and immunomodulatory therapy) 7. history of immunocompromised state. 8. history of psychiatric illness. 9. history of psoriasis or porphyria. 10. history of cardiac disease. 11. other major comorbidities that contraindicate the use of hcq: i. hematologic malignancy, ii. stage 4-5 chronic kidney disease or end-stage renal failure, iii. history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval 12. history of severe skin reactions such as stevens-johnson syndrome and toxic epidermal necrolysis. 13. bradycardia \<50beats/min. 14. uncorrected hypokalemia 15. uncorrected hypomagnesemia. 16. unwillingness to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) while on study and for at least 30 days after last dose.

1. person diagnosed with covid-19 infection. 2. pregnant at the time of screening or breastfeeding. 3. known allergy or hypersensitivity to hcq or other aminoquinoline compounds. 4. already on hcq for different indications (e.g., rheumatological diseases, malaria prophylaxis) 5. diagnosis of other systemic viral or bacterial infection. 6. use of systemic immunosuppressant agents within 90 days of enrollment (e.g., corticosteroids and immunomodulatory therapy) 7. history of immunocompromised state. 8. history of psychiatric illness. 9. history of psoriasis or porphyria. 10. history of cardiac disease. 11. other major comorbidities that contraindicate the use of hcq: i. hematologic malignancy, ii. stage 4-5 chronic kidney disease or end-stage renal failure, iii. history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval 12. history of severe skin reactions such as stevens-johnson syndrome and toxic epidermal necrolysis. 13. bradycardia \<50beats/min. 14. uncorrected hypokalemia 15. uncorrected hypomagnesemia. 16. unwillingness to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) while on study and for at least 30 days after last dose.

person diagnosed with covid-19 infection. pregnant at the time of screening or breastfeeding. known allergy or hypersensitivity to hcq or other aminoquinoline compounds. already on hcq for different indications (e.g., rheumatological diseases, malaria prophylaxis) diagnosis of other systemic viral or bacterial infection. use of systemic immunosuppressant agents within 90 days of enrollment (e.g., corticosteroids and immunomodulatory therapy) history of immunocompromised state. history of psychiatric illness. history of psoriasis or porphyria. history of cardiac disease. other major comorbidities that contraindicate the use of hcq: i. hematologic malignancy, ii. stage 4-5 chronic kidney disease or end-stage renal failure, iii. history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval history of severe skin reactions such as stevens-johnson syndrome and toxic epidermal necrolysis. bradycardia <50beats/min. uncorrected hypokalemia uncorrected hypomagnesemia. unwillingness to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) while on study and for at least 30 days after last dose.

person diagnosed with covid-19 infection. pregnant at the time of screening or breastfeeding. known allergy or hypersensitivity to hcq or other aminoquinoline compounds. already on hcq for different indications (e.g., rheumatological diseases, malaria prophylaxis) diagnosis of other systemic viral or bacterial infection. use of systemic immunosuppressant agents within 90 days of enrollment (e.g., corticosteroids and immunomodulatory therapy) history of immunocompromised state. history of psychiatric illness. history of psoriasis or porphyria. history of cardiac disease. other major comorbidities that contraindicate the use of hcq: i. hematologic malignancy, ii. stage 4-5 chronic kidney disease or end-stage renal failure, iii. history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval history of severe skin reactions such as stevens-johnson syndrome and toxic epidermal necrolysis. bradycardia <50beats/min. uncorrected hypokalemia uncorrected hypomagnesemia. unwillingness to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) while on study and for at least 30 days after last dose.

1. person diagnosed with covid-19 infection. 2. pregnant at the time of screening or breastfeeding. 3. known allergy or hypersensitivity to hcq or other aminoquinoline compounds. 4. already on hcq for different indications (e.g., rheumatological diseases, malaria prophylaxis) 5. diagnosis of other systemic viral or bacterial infection. 6. use of systemic immunosuppressant agents within 90 days of enrollment (e.g., corticosteroids and immunomodulatory therapy) 7. history of immunocompromised state. 8. history of psychiatric illness. 9. history of psoriasis or porphyria. 10. history of cardiac disease. 11. other major comorbidities that contraindicate the use of hcq: i. hematologic malignancy, ii. stage 4-5 chronic kidney disease or end-stage renal failure, iii. history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval 12. history of severe skin reactions such as stevens-johnson syndrome and toxic epidermal necrolysis. 13. bradycardia <50beats/min. 14. uncorrected hypokalemia 15. uncorrected hypomagnesemia. 16. unwillingness to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) while on study and for at least 30 days after last dose.

1. person diagnosed with covid-19 infection. 2. pregnant at the time of screening or breastfeeding. 3. known allergy or hypersensitivity to hcq or other aminoquinoline compounds. 4. already on hcq for different indications (e.g., rheumatological diseases, malaria prophylaxis) 5. diagnosis of other systemic viral or bacterial infection. 6. use of systemic immunosuppressant agents within 90 days of enrollment (e.g., corticosteroids and immunomodulatory therapy) 7. history of immunocompromised state. 8. history of psychiatric illness. 9. history of psoriasis or porphyria. 10. history of cardiac disease. 11. other major comorbidities that contraindicate the use of hcq: i. hematologic malignancy, ii. stage 4-5 chronic kidney disease or end-stage renal failure, iii. history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval 12. history of severe skin reactions such as stevens-johnson syndrome and toxic epidermal necrolysis. 13. bradycardia <50beats/min. 14. uncorrected hypokalemia 15. uncorrected hypomagnesemia. 16. unwillingness to practice acceptable methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) while on study and for at least 30 days after last dose.